Stem Cell Pioneer to Speak to ALL Personhood Conference

January 12, 2009 09:00 AM

Washington, D.C. (12 January 2009) – American Life League's historic Personhood Conference is featuring one the foremost pioneers in adult stem cell research and regenerative medicine.

Dr. Theresa Deisher, founder and CEO of AVM Biotechnology and President of Sound Choice Pharmaceutical Institute, is speaking on over 17 years of experience in scientific research, discovery, production and commercialization of human therapeutics at 2:30 p.m. on Jan. 23 at the Liaison Hotel in Washington, D.C.

"We are thrilled to have Dr. Deisher speak on the exciting promise of adult stem cells," said Judie Brown, president of American Life League. "Adult stem cell research is providing cures and therapies for countless medical conditions and yet we seldom hear about the exciting power of these medical wonders."

Brown continued, "While the world and the media would have us believe that embryonic stem cells are the panacea to cure the world's ills, the reality is only adult stem cells have been shown to hold such power."

Dr. Deisher's work has resulted in 23 patents issued in her name. She has published numerous scientific manuscripts and is a frequent invited lecturer and guest speaker in the area of stem cell technology and regenerative medicine.

Dr. Deisher joins an illustrious group of speakers heralding the return of the personhood movement including keynote speaker Judie Brown; Ambassador Alan Keyes, founder and chairman of the Declaration Foundation; 40 Days for Life leader David Bereit; Kristi Burton, architect of the Colorado personhood movement; and Lila Rose, president of Live Action Films.

American Life League was cofounded in 1979 by Judie Brown. It is the largest grassroots Catholic pro-life organization in the United States and is committed to the protection of all innocent human beings from the moment of creation to death.  For more information or press inquiries, please contact Katie Walker at 540.659.4942. 

FOR MORE INFORMATION:
 

Back to news